Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4272721 | The Journal of Sexual Medicine | 2008 | 11 Pages |
Abstract
Both treatments resulted to improved overall sexual function, as determined by scores on the FSFI, an increase in the frequency of sexual events, and a reduction in sexuality-related personal distress. The statistically significant higher FSFI scores in the tibolone group, when compared to the E2/NETA group, may be because of tibolone's combined estrogenic and androgenic properties. Nijland EA, Schultz WCMW, Nathorst-Boös J, Helmond FA, Van Lunsen RHW, Palacios S, Norman RJ, Mulder RJ, and Davis SR for the LISA study investigators. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: Results of a randomized active-controlled trial
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Esme A. MD, Willibrord C.M. Weijmar MD, PhD, Jörgen MD, PhD, Frans A. MD, PhD, Rik H.W. MD, PhD, Santiago MD, Robert J. MD, PhD, Roel J. MSc, Susan R. MD, PhD, LISA study investigators LISA study investigators,